AI Platform Aims to Revolutionize Cancer Immunotherapy
/0 Comments/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxA new AI platform developed by researchers at the Technical University of Denmark and the Scripps Research Institute has dramatically accelerated the design of specialized protein molecules called “minibinders” to enhance cancer immunotherapy. Normally, T cells recognize cancer cells by detecting protein fragments (peptides) presented on their surface by molecules known as pMHCs, but harnessing […]
New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets
/0 Comments/in Immunotherapy, Preclinical Research/by MaxScientists Trace Deadly Shift in Prostate Cancer to Two Key Genes
/0 Comments/in Preclinical Research/by MaxTaiwanese Study Uncovers Cancer-Fighting Potential of Common Allergy Drug
/0 Comments/in Drug repurposing, Preclinical Research/by MaxCRISPR: Gene Breakthrough Could Starve Cancer Cells of Vitamin D
/0 Comments/in CRISPR, Preclinical Research/by MaxBreakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/0 Comments/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
Korean Team Unveils Breakthrough All-in-One Cancer Nanomedicine
/0 Comments/in Preclinical Research/by MaxIn a groundbreaking advancement for cancer treatment, a team from the Korea Research Institute of Standards and Science (KRISS) has developed an innovative nanomaterial that could transform cancer care. This “all-in-one” nanomedicine, known as gold-iron-gold nanodisks (AuFeAuNDs), integrates diagnosis, treatment, and immune activation into a single platform. Still in pre-clinical stages, this discovery shows significant […]
MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC
/0 Comments/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
Latest Posts
- Phase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors July 30, 2025
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025